Nab-paclitaxel 100 mg/m^2

DRUG3 trials

Conditions

AdenocarcinomaCarcinoma, Pancreatic DuctalFallopian Tube NeoplasmsNon-small Cell Lung CancerOvarian NeoplasmPeritoneal NeoplasmsSmall Cell Lung CancerSolid Tumor

Phase 1

Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)

CompletedNCT01840579

Merck Sharp & Dohme LLCNon-small Cell Lung Cancer, Small Cell Lung Cancer, Solid Tumor

Start: 2013-04-26End: 2020-02-28Updated: 2021-06-22

Phase 2

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

RecruitingNCT07259317

Corcept TherapeuticsAdenocarcinoma, Carcinoma, Pancreatic Ductal

Start: 2026-01-27End: 2027-07-01Target: 60Updated: 2026-03-27

Phase 3

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Active, not recruitingNCT05257408

Corcept TherapeuticsFallopian Tube Neoplasms, Ovarian Neoplasm, Peritoneal Neoplasms

Start: 2022-06-29End: 2026-03-31Updated: 2025-04-16

Journal of Clinical Oncology2025-06-043 citations

Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.

2025-06-0212 citations

A phase 1 study of pembrolizumab plus ipilimumab as first-line treatment in Japanese patients with advanced non-small-cell lung cancer.

2025-03-03

Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer.

2024-07-015 citations

Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer.

2024-02-01

TP019/#1387 Rosella (GOG-3073, ENGOT-OV72/MITO): a phase 3 study of relacorilant + nab paclitaxel vs. nab-paclitaxel in platinum-resistant ovarian cancer

2023-11-011 citations

#205 ROSELLA (GOG-3073, ENGOT-Ov72/MITO): a phase 3 study of relacorilant + nab-paclitaxel vs. nab-paclitaxel in advanced, platinum-resistant ovarian cancer

2023-09-013 citations

Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study

Journal of Clinical Oncology2023-06-2631 citations

Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.

Journal of Clinical Oncology2022-06-086 citations

Phase 1 study of pembrolizumab plus chemotherapy as first-line treatment in Japanese patients with advanced NSCLC.

2021-09-153 citations

Nab-paclitaxel 100 mg/m^2

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Related Papers